BRPI0814260A2 - Motivos de sequências de rna no contexto de ligações internucleotídeos definidas induzindo perfis imunomoduladores específicos - Google Patents

Motivos de sequências de rna no contexto de ligações internucleotídeos definidas induzindo perfis imunomoduladores específicos

Info

Publication number
BRPI0814260A2
BRPI0814260A2 BRPI0814260A BRPI0814260A2 BR PI0814260 A2 BRPI0814260 A2 BR PI0814260A2 BR PI0814260 A BRPI0814260 A BR PI0814260A BR PI0814260 A2 BRPI0814260 A2 BR PI0814260A2
Authority
BR
Brazil
Prior art keywords
profiles
context
rna sequence
internucleotide linkages
sequence motifs
Prior art date
Application number
Other languages
English (en)
Inventor
Marion Jurk
Jorg Heinz Vollmer
Original Assignee
Coley Pharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40351228&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0814260(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Coley Pharm Gmbh filed Critical Coley Pharm Gmbh
Publication of BRPI0814260A2 publication Critical patent/BRPI0814260A2/pt
Publication of BRPI0814260B1 publication Critical patent/BRPI0814260B1/pt
Publication of BRPI0814260B8 publication Critical patent/BRPI0814260B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
BRPI0814260A 2007-08-13 2008-08-08 composição compreendendo um polímero de fita única, método compreendendo contatar uma célula com tal polímero e uso de tal polímero BRPI0814260B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96444807P 2007-08-13 2007-08-13
PCT/IB2008/002104 WO2009022216A2 (en) 2007-08-13 2008-08-08 Rna sequence motifs in the context of defined internucleotide linkages inducing specific immune modulatory profiles

Publications (3)

Publication Number Publication Date
BRPI0814260A2 true BRPI0814260A2 (pt) 2015-03-31
BRPI0814260B1 BRPI0814260B1 (pt) 2019-11-12
BRPI0814260B8 BRPI0814260B8 (pt) 2021-05-25

Family

ID=40351228

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0814260A BRPI0814260B8 (pt) 2007-08-13 2008-08-08 composição compreendendo um polímero de fita única, método compreendendo contatar uma célula com tal polímero e uso de tal polímero

Country Status (23)

Country Link
US (3) US8128944B2 (pt)
EP (1) EP2179039B1 (pt)
JP (1) JP4847609B2 (pt)
KR (1) KR20100045508A (pt)
CN (1) CN101821392B (pt)
AR (1) AR067928A1 (pt)
AU (1) AU2008288241B2 (pt)
BR (1) BRPI0814260B8 (pt)
CA (1) CA2696630C (pt)
CL (1) CL2008002371A1 (pt)
CO (1) CO6260153A2 (pt)
DK (1) DK2179039T3 (pt)
ES (1) ES2703876T3 (pt)
HK (1) HK1143741A1 (pt)
MX (1) MX2010001014A (pt)
NZ (1) NZ582972A (pt)
PL (1) PL2179039T3 (pt)
PT (1) PT2179039T (pt)
RU (1) RU2435851C2 (pt)
SI (1) SI2179039T1 (pt)
TR (1) TR201820474T4 (pt)
TW (1) TW200916106A (pt)
WO (1) WO2009022216A2 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101821392B (zh) * 2007-08-13 2013-04-17 科勒制药有限责任公司 在限定核苷酸间键环境下的诱导特异性免疫调节特性的rna序列基序
JP2010536907A (ja) * 2007-08-31 2010-12-02 ニューリミューン セラピューティクス エイジー 患者にアミロイドーシスおよびタンパク質凝集性障害における特異的免疫応答をもたらす方法
US10383887B2 (en) 2008-02-20 2019-08-20 New York University Preventing and treating amyloid-beta deposition by stimulation of innate immunity
US9844592B2 (en) * 2011-07-18 2017-12-19 Icahn School Of Medicine At Mount Sinai Bacterial RNAs as vaccine adjuvants
US10434064B2 (en) * 2014-06-04 2019-10-08 Exicure, Inc. Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
CN107106493A (zh) 2014-11-21 2017-08-29 西北大学 球形核酸纳米颗粒缀合物的序列特异性细胞摄取
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
SG11202004471RA (en) * 2017-12-15 2020-06-29 Bayer Animal Health Gmbh Immunostimulatory oligonucleotides
WO2024030844A1 (en) * 2022-08-01 2024-02-08 University Of Mississippi Choline carboxylic acid based ionic liquids as antimicrobial agents

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1446162B1 (en) 2001-08-17 2008-10-15 Coley Pharmaceutical GmbH Combination motif immune stimulatory oligonucleotides with improved activity
NZ573064A (en) 2002-04-04 2011-02-25 Coley Pharm Gmbh Immunostimulatory G,U-containing oligoribonucleotides
CN1302948C (zh) 2002-04-12 2007-03-07 爱信艾达株式会社 车载装置用电源管理系统
DE10229872A1 (de) * 2002-07-03 2004-01-29 Curevac Gmbh Immunstimulation durch chemisch modifizierte RNA
WO2004053104A2 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5’ cpg nucleic acids and methods of use
US20060074040A1 (en) 2003-07-15 2006-04-06 Hybridon, Inc. Synergistic stimulation of the immune system using immunostimulatory oligonucleotides and/or immunomer compounds in conjunction with cytokines and/or chemotherapeutic agents or radiation therapy
US20050239733A1 (en) 2003-10-31 2005-10-27 Coley Pharmaceutical Gmbh Sequence requirements for inhibitory oligonucleotides
JP2007526253A (ja) * 2004-02-19 2007-09-13 コーリー ファーマシューティカル グループ，インコーポレイテッド 免疫刺激性ウイルスｒｎａオリゴヌクレオチド
MY159370A (en) * 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
WO2007031322A1 (en) 2005-09-14 2007-03-22 Gunther Hartmann Compositions comprising immunostimulatory rna oligonucleotides and methods for producing said rna oligonucleotides
BRPI0622298A8 (pt) 2005-11-25 2016-04-05 Coley Pharm Gmbh Oligorribonucleotídeo para estimular a produção de uma citocina pró-inflamatória, uso do mesmo e composição contendo tal oligorribonucleotídeo
CN101821392B (zh) 2007-08-13 2013-04-17 科勒制药有限责任公司 在限定核苷酸间键环境下的诱导特异性免疫调节特性的rna序列基序

Also Published As

Publication number Publication date
NZ582972A (en) 2011-09-30
TR201820474T4 (tr) 2019-01-21
US8466124B2 (en) 2013-06-18
CO6260153A2 (es) 2011-03-22
RU2435851C2 (ru) 2011-12-10
CL2008002371A1 (es) 2009-07-03
CN101821392B (zh) 2013-04-17
EP2179039A2 (en) 2010-04-28
ES2703876T3 (es) 2019-03-12
DK2179039T3 (en) 2019-01-07
CN101821392A (zh) 2010-09-01
JP2010536739A (ja) 2010-12-02
CA2696630C (en) 2014-04-01
RU2010104618A (ru) 2011-09-20
WO2009022216A3 (en) 2009-06-04
JP4847609B2 (ja) 2011-12-28
AU2008288241A1 (en) 2009-02-19
US8128944B2 (en) 2012-03-06
MX2010001014A (es) 2010-03-01
KR20100045508A (ko) 2010-05-03
US20100272785A1 (en) 2010-10-28
BRPI0814260B1 (pt) 2019-11-12
PT2179039T (pt) 2019-01-11
AU2008288241B2 (en) 2011-12-01
WO2009022216A9 (en) 2009-04-30
EP2179039B1 (en) 2018-10-31
PL2179039T3 (pl) 2019-03-29
US20120121648A1 (en) 2012-05-17
CA2696630A1 (en) 2009-02-19
US20120258140A1 (en) 2012-10-11
BRPI0814260B8 (pt) 2021-05-25
US8227447B2 (en) 2012-07-24
WO2009022216A2 (en) 2009-02-19
AR067928A1 (es) 2009-10-28
TW200916106A (en) 2009-04-16
SI2179039T1 (sl) 2019-01-31
HK1143741A1 (en) 2011-01-14

Similar Documents

Publication Publication Date Title
BRPI0814260A2 (pt) Motivos de sequências de rna no contexto de ligações internucleotídeos definidas induzindo perfis imunomoduladores específicos
GB201014134D0 (en) Methods of RNA aplification in the presence of DNA
BRPI0817265A2 (pt) Vacina de rna, uso de pelo menos uma molécula de rna, e, molécula de rna isolada
DK1957528T3 (da) Nukleotid-vaccine
EP2268813A4 (en) RNA MOLECULES AND THEIR USE
EP2198022C0 (en) ARMADILLO REPEAT DESIGNER PROTEINS
DE602007003596D1 (de) Impfstoff
AR058706A1 (es) Vacuna
BRPI0811170A2 (pt) Oligonucleotídeos de rna e complexos de rna substituídos por hidroximetila
BRPI0718796A2 (pt) Nucleotídeo
DK2190991T3 (da) SDF-1-Bindende nucleinsyrer og anvendelsen deraf
CR10571A (es) Vacuna virica recombinante
DK2114993T3 (da) Vaccine
IL185917A0 (en) Immunogenic molecules
GB0612301D0 (en) DNA molecules and methods
EP2215252A4 (en) MEGANUCLEASES DESIGNED RATIONALLY WITH IDENTIFICATION SEQUENCES FOUND IN HUMAN GENOME DNAASE HYPERSENSIVE REGIONS
DE602008000522D1 (de) Dissektionsvorrichtung
DK2081950T3 (da) Med irinotecanbehandling forbundne ekspressionsprofiler
BRPI0815604A2 (pt) Proteínas de streptococcus imunogênicas
FR2914165B3 (fr) Couffin protatif de forme ovoide
DE502005000305D1 (de) Photobioreaktor
BRPI0810656A2 (pt) Produto hidroformado
BRPI0821812A2 (pt) Remoção de silício da salmoura
DK2154144T3 (da) Oligonukleotider og anvendelse deraf
HRP20130643T1 (hr) Dnk-plazmidi koji imaju poboljšanu ekspresiju i stabilnost

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: PFIZER ANIMAL HEALTH S.A. (US)

B25D Requested change of name of applicant approved

Owner name: ZOETIS BELGIUM S.A. (BE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/11/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/11/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/08/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF